Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
2020年12月21日 更新者:Octapharma
Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Patients With Severe Hemophilia A
The purpose of this study is to obtain additional data on the safety and efficacy of Wilate in PTPs with hemophilia A with at least 150 previous exposure days (EDs) to a FVIII concentrate who undergo prophylactic treatment with Wilate for 6 months and at least 50 EDs, thus supplementing the existing database to obtain approval of Wilate for the indication hemophilia A in the USA.
研究概览
研究类型
介入性
注册 (实际的)
57
阶段
- 第三阶段
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
-
Barnaul、俄罗斯联邦
- Barnaul Branch of RAMS hematology center
-
Moscow、俄罗斯联邦
- Federal Scientific Hematology Center
-
-
-
-
-
Sofia、保加利亚
- Specialized Hospital for Active Treatment "Joan Pavel"
-
-
-
-
-
Budapest、匈牙利
- National Haemophilia Centre
-
-
-
-
-
Krakow、波兰
- Krakowskie Centrum Medyczne
-
Rzeszow、波兰
- Korczowski Bartosz Gabinet Lekarski
-
-
-
-
-
Bucharest、罗马尼亚
- Centrul Medical Unirea -Policlinica Enescu
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
12年 及以上 (孩子、成人、年长者)
接受健康志愿者
不
有资格学习的性别
男性
描述
Inclusion Criteria:
- Severe hemophilia A (<1% FVIII:C) according to medical history
- Male patients aged ≥12 years
- Previous treatment with a FVIII concentrate for at least 150 exposure days (EDs)
- Immunocompetence (CD4+ count >200/µL)
- Good documentation of the historical bleeding rate (at least for the 6 months preceding study start)
- Voluntarily given, fully informed written and signed consent obtained by the patient (or parent/legal guardian in case of adolescents) before any study-related procedures are conducted
Whenever possible, the interval between the Screening Visit and the PK or Non-PK Visit should not exceed 30 days. If the 30-day interval is exceeded, determination of the CD4+ count is to be repeated and must be >200/µL for patients to be enrolled (i.e., exclusion criterion no. 4).
Exclusion Criteria:
- Any coagulation disorders other than hemophilia A
- History of FVIII inhibitor activity (≥0.6 BU) or detectable FVIII inhibitory anti-bodies (≥0.6 BU using the Nijmegen modification of the Bethesda assay) at screening, as determined by the central laboratory
- Severe liver or kidney diseases (alanine aminotransferase [ALAT] and aspartate transaminase [ASAT] levels >5 times of upper limit of normal, creatinine>120 µmol/L)
- Patients receiving or scheduled to receive immunomodulating drugs (other than anti-retroviral chemotherapy) such as alpha-interferon, prednisone (equivalent to >10 mg/day), or similar drugs
- Treatment with any investigational medicinal product in another interventional clinical study currently or within 4 weeks before enrollment
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:All patients
All patients will receive Wilate for prophylactic treatment
|
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Total Annualized Bleeding Rate (TABR)
大体时间:6 months
|
The total number of bleeding events (BEs) was documented by patients in a patient diary (together with the investigator in case of on-site treatments), which was reviewed at each follow-up visit by site personnel.
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Spontaneous Annualized Bleeding Rate (SABR)
大体时间:6 months
|
The number of spontaneous bleeding events (BEs) was documented by patients in a patient diary (together with the investigator in case of on-site treatments), which was reviewed at each follow-up visit by site personnel.
|
6 months
|
Efficacy of Wilate in the Treatment of Breakthrough BEs
大体时间:6 months
|
The proportion of BEs successfully treated with Wilate were documented by the patient (together with the investigator in case of on-site treatments) in the patient diary for all BEs according to a 4-point hemostatic efficacy scale including the four items: 'excellent,' 'good,' moderate,' and 'none', where 'excellent' was defined as "Abrupt pain relief and/or unequivocal improvement in objective signs of bleeding within approximately 8 hours after a single injection" (best outcome) and 'none' was defined as "No improvement within 12 hours, or worsening of symptoms, requiring more than two injections for complete resolution" (worst outcome).
All efficacy ratings assessed as either 'excellent' or 'good' were considered 'successfully treated.'
|
6 months
|
Wilate Consumption Data (Average Total Normdose of FVIII IU/kg Per Month of Study) for Prophylaxis
大体时间:6 months
|
The average consumption of Wilate per month of study (IU/kg) for all patients receiving prophylaxis.
|
6 months
|
Pharmacokinetic (PK) Assessment (Area Under the Curve [AUC] Norm) of FVIII:C
大体时间:Initial PK visit (Day -1) and PK study completion visit (6 months); data collected 1 h prior to injection and 15 min, 1 h, 3 h, 6 h, 9 h, 24 h, 30 h and 48 h after the end of injection
|
PK assessments of FVIII:C were conducted using the one-stage (OS) assay.
The value of the AUCnorm of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study.
|
Initial PK visit (Day -1) and PK study completion visit (6 months); data collected 1 h prior to injection and 15 min, 1 h, 3 h, 6 h, 9 h, 24 h, 30 h and 48 h after the end of injection
|
Pharmacokinetic (PK) Assessment (in Vivo Half-Life (t1/2)) of FVIII:C
大体时间:Initial PK assessment (Day -1) and PK study completion visit (6 months); data collected 1 h prior to infusion and 15 min, 1 h, 3 h, 6 h, 9 h, 24 h, 30 h and 48 h after the end of injection
|
PK assessments of FVIII:C were conducted using the one-stage (OS) assay.
The in vivo half-life of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study.
|
Initial PK assessment (Day -1) and PK study completion visit (6 months); data collected 1 h prior to infusion and 15 min, 1 h, 3 h, 6 h, 9 h, 24 h, 30 h and 48 h after the end of injection
|
Pharmacokinetic (PK) Assessment (Maximum Plasma Concentration [Cmax]) of FVIII:C
大体时间:Initial PK assessment (Day -1) and 6 months
|
PK assessments of FVIII:C were conducted using the one-stage (OS) assay.
The maximum plasma concentration of FVIII:C was calculated based on the FVIII:C values measured in the patients participating in the PK study.
|
Initial PK assessment (Day -1) and 6 months
|
Incremental in Vivo Recovery (IVR) of Wilate Over Time
大体时间:Baseline, 3 and 6 months
|
The rise in FVIII activity in IU/dl per unit dose administered in IU/kg was determined from all patients at baseline, 3 and 6 months, using the OS assay.
|
Baseline, 3 and 6 months
|
Association Between ABO Blood Type and the FVIII:C Half-life of Wilate (OS Assay)
大体时间:6 months
|
Analysis of variance (ANOVA) was used in an exploratory sense to assess an association between ABO blood type and the FVIII:C half-life of Wilate.
This was analyzed by calculating the mean square in a one-stage assay.
|
6 months
|
Association Between VWF:Ag Concentration and the FVIII:C Half-life of Wilate
大体时间:6 months
|
ANOVA was used in an exploratory sense to assess an association between VWF:Ag with the FVIII:C half-life of Wilate.
This was analyzed by calculating the mean square in a one-stage assay.
|
6 months
|
Safety and Tolerability of Wilate by Monitoring Adverse Events (AEs) Throughout the Study
大体时间:6 months
|
At each (scheduled or unscheduled) study visit, AEs were documented by the investigator throughout the study.
|
6 months
|
Immunogenicity of Wilate by Testing for FVIII Inhibitors
大体时间:6 months
|
FVIII inhibitor activity was determined at each study visit before the injection of Wilate using the modified Bethesda assay (Nijmegen modification).
|
6 months
|
Virus Safety Measured by the Number of Parvovirus B19 Seroconversions Between Baseline (BL) and End of Study
大体时间:6 months
|
Virus safety was evaluated by taking a plasma sample for parvovirus B19 antibody testing before the first injection of Wilate.
All patients negative at screening were tested again at the study completion visit.
The number with Parvovirus B19 seroconversions between BL and end of study was recorded.
|
6 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Efficacy of Wilate in Surgical Prophylaxis
大体时间:6 months
|
Hemostatic efficacy was assessed at the end of surgery by the surgeon and at end of the postoperative period by the hematologist, using a 4-point hemostatic efficacy scale including the four items: 'excellent' (best possible outcome), 'good', 'moderate' and 'none' (worst outcome).
Overall efficacy was assessed by the investigator, taking both the intra and postoperative assessments into account, and using the 'excellent,' 'good,' moderate,' and 'none' scale.
|
6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2016年12月1日
初级完成 (实际的)
2018年3月29日
研究完成 (实际的)
2018年3月29日
研究注册日期
首次提交
2016年10月27日
首先提交符合 QC 标准的
2016年11月1日
首次发布 (估计)
2016年11月3日
研究记录更新
最后更新发布 (实际的)
2021年1月19日
上次提交的符合 QC 标准的更新
2020年12月21日
最后验证
2020年12月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
严重血友病 A的临床试验
-
Cheikh Anta Diop University, SenegalInternational Atomic Energy Agency尚未招聘
-
University of California, DavisBill and Melinda Gates Foundation; Penn State University; Newcastle University; Helen Keller International 和其他合作者完全的
-
Ionis Pharmaceuticals, Inc.Akcea Therapeutics完全的
-
Institute of Nutrition of Central America and PanamaBill and Melinda Gates Foundation; Newcastle University; International Atomic Energy Agency完全的
-
Medical University of Vienna完全的
-
Tufts UniversityNutricia Research Fundation; National University of Science and Technology, Zimbabwe完全的
Wilate的临床试验
-
BloodworksErgomed; Octapharma; Mary M. Gooley Hemophilia Center招聘中